IMV receives notification from Nasdaq regarding market value of listed securities
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.–(BUSINESS WIRE)–IMV Inc. (“IMV“or the”Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® solid and hematological cancer treatment platform, today announced that on November 22, 2022, the Company received a notification letter from the Listing Qualifications Department of The Nasdaq …
IMV receives notification from Nasdaq regarding market value of listed securities Read More »
